Aminoglutethimide in advanced breast cancer: Prospective, randomized comparison of two dose levels

G. Robustelli Della Cuna, F. Pannuti, A. Martoni, C. M. Camaggi, E. Strocchi, G. A. Da Prada, S. Tanneberger

Research output: Contribution to journalArticlepeer-review


In a multicenter randomized clinical trial 106 postmenopausal patients with progressive metastatic breast cancer were allocated to receive 500 mg or 1000 mg Aminoglutethimide (AG) per os daily. Cortisone Acetate (CA) replacement dose was 37.5 mg/day orally in both groups. In 91 fully evaluable patients no statistically significant difference was observed between the two therapeutic regimens neither in terms of overall response (28 vs 35%) and by site responses nor in terms of median time to progression (10.5 vs 14.5 months) and media)l overall survival (20 vs. 22 months). The tolerability was satisfactory in both regimens. Although no statistically significant differences occurred in the low dose regimen we observed fewer patients with side-effects (25% vs 6%) and induced grade 3 side-effects (4% vs 9%). Our results confirm that AG daily doses of 500 and 1000 mg associated with corticosteroids have a comparable effect. Because of its slight but clinically noticeable better tolerability, the lower dose is the preferable regimen in the treatment of advanced breast cancer.

Original languageEnglish
Pages (from-to)2367-2371
Number of pages5
JournalAnticancer Research
Issue number6 B
Publication statusPublished - 1993


  • Aminoglutethimide
  • Metastatic breast cancer
  • Optimal daily dose
  • Randomized study

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Aminoglutethimide in advanced breast cancer: Prospective, randomized comparison of two dose levels'. Together they form a unique fingerprint.

Cite this